Rechon Insulin Human Soluble

Rechon Insulin Human Soluble is a recombinant human insulin biosimilar developed by Rechon Life Science AB, a Swedish pharmaceutical contract manufacturer. It is a short-acting (soluble) insulin intended for the treatment of diabetes mellitus, specifically type 1 diabetes, to control blood glucose levels. As a biosimilar to Eli Lilly's Humulin Regular, it acts as an agonist at the insulin receptor (INSR), mimicking the activity of endogenous human insulin to stimulate peripheral glucose uptake and inhibit hepatic glucose production. The drug is administered via subcutaneous injection. Although it reached Phase 3 clinical development, where its long-term safety and immunogenicity were compared to Humulin Regular, the marketing authorization application to the European Medicines Agency (EMA) was withdrawn in March 2025 after the agency indicated that the provided data were insufficient to demonstrate biosimilarity.

Brand names

Rechon Insulin Human Soluble